Undisclosed RNA-targeted small molecule / Arrakis Therap - LARVOL DELTA

Arrakis Therapeutics Announces Oral Presentation Describing RNA-targeted Small Molecule to Treat Myotonic Dystrophy at MDA Conference 2025 (Businesswire) - "Arrakis Therapeutics...today announced that the company will present preclinical data for its RNA-targeted small molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1), a form of muscular dystrophy. The data will be presented in an oral session at the Muscular Dystrophy Association (MDA) 2025 Clinical and Scientific Conference taking place on March 16-19 in Dallas, Texas."

Preclinical • Myotonic Dystrophy